
    
      Study Design: Intervention Model: Single Group Assignment

      Masking: Open Label

      Primary Outcome Measures:

      Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation
      group and control group.

      Secondary Outcome Measures:

      Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control
      group.

      Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control
      group.

      Safety of intravesical 2000mg/52.6ml gemcitabine instillation.
    
  